$7.96
1.24%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US6700021040
Symbol
NVAX

Novavax, Inc. Stock News

Neutral
●
PRNewsWire
●
6 days ago
GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London Healthcare Conference, London, United KingdomFireside chat on Tuesday, November 17, 2026, at 5:00 p.m.
Neutral
●
PRNewsWire
●
13 days ago
Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point  In October, Novavax earned a $125 million milestone upon Sanofi's launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe Sanofi ...
Neutral
●
PRNewsWire
●
20 days ago
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royal...
Neutral
●
Reuters
●
about one month ago
Shah Capital, one of Novavax's top shareholders, said on Friday ​it no longer seeks to influence ‌control of the vaccine maker after restructuring into a family office.
Negative
●
Barrons
●
about one month ago
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Neutral
●
PRNewsWire
●
3 months ago
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients GAITHERSBURG, Md., Aug. 28, 2026 /PRNewswire/ -- Novavax, Inc.'s (Nasdaq: NVAX) partners have ...
Positive
●
Reuters
●
3 months ago
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and ​Pfizer-BioNTech's updated COVID vaccines, the companies ‌said on Thursday, after an advisory panel recommended that the shots should target ​the dominant XFG variant.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today